Small molecule drug, Niraparib combined with abiraterone acetate (AA) and prednisone (P) significantly reduces the risk of disease progression, or death, in patients with a type of prostate cancer, a consultant in Spain has said.
A renowned university researcher explains the path that laid the foundation and what the novel diagnostic and treatment means for prostate cancer patients.
The clinical-stage biotech firm and a number of high-profile partners have collaborated on biomarker technology to deliver a more accurate, less invasive option.
Crown Bioscience has expanded its portfolio of non-animal based disease models by licensing a range of cellular prostate cancer models developed by UK academics.
Novartis subsidiary Sandoz will commercialise small and large molecule injectables using French delivery tech firm MedinCell’s subcutaneous controlled release platform.
AstraZeneca says it would never outsource the manufacture of Zoladex after announcing plans to invest £120m ($190m) in a fifth production facility for the blockbuster cancer drug.
GSK says it will start making its BPH drug Avodart (dutasteride) at its facility in Poznan, Poland when it completes a PLN70m (€17m) capacity upgrade in January next year.
Merck & Co has inked a deal potentially worth over $507m
(€346m) with GTx over a new class of drugs to treat muscle loss
conditions, especially those caused by cancer.
After decades of limited options and false hopes, prostate cancer
sufferers will be hoping AstraZeneca's (AZ) new drug can succeed
where Abbott's failed.
LabTechnologist.com brings you its periodic round up of new product
releases and product news, with new offerings from Aura, Horiba
Jobin Yvon, Integra, Metrohm, Millipore, Promega, Roche and Thermo
Fisher Scientific.
US drug regulators have requested more proof that Dendreon's
prostate cancer treatment works before they will approve it,
sending the Seattle-based biotech's shares plummeting.
Positive results from trials of Cell Genesys's latest immunotherapy
treatment, GVAX, show that the therapy induces a broad immune
response in prostate cancer sufferers that is patient specific.
US company DOR BioPharma plans to start clinical trials in the next
few months with what could be the first oral formulation of the
widely used prostate cancer treatment leuprolide.
Private pharmaceutical firm Tolmar has sold off its pharmaceutical
manufacturing plant in a move to fund the purchase of the US assets
of biopharmaceutical QLT. The plant, sold for $13.6m (€10.5m), will
be leased back to Tolmar under...
Dendreon has finished the construction of its New Jersey
manufacturing facility which it will use to produce its
investigational active cellular immunotherapy for advanced prostate
cancer, hoping to be the first to bring it to patients.
European researchers have not only devised a new diagnostic lab
tool for prostate cancer but have also identified a new molecular
marker that makes the identification of the disease much quicker.
Anticipating a US Food and Drug Administration (FDA) approval this
year, Dendreon has awarded Diosynth Biotechnology with a long-term
contract to supply the recombinant protein antigen component of its
novel vaccine for prostate cancer...
Scientists have admitted that an unexpected genetic phenomenon in
prostate cancer has changed conventional thinking over approaches
in drug treatment of breast, colon and lung malignancies.
Millenium Pharmaceuticals has announced final results from a
clinical trial of MLN2704, a novel antibody intended for the
chemotherapeutic treatment of advanced hormone-refractory prostate
cancer.
Biopharmaceutical company, Insmed, are to commence clinical
development of a small molecule tyrosine kinase inhibitor, which
has demonstrated anti-tumour activity in preclinical studies of
breast, lung, pancreatic and prostate tumours.
A drug derived from a natural source - the cottonseed rape plant -
could find a new application as a cancer drug after failing to
prove itself as a male contraceptive.
Scientists have determined the precise molecular structure of a
potential new target for treating prostate cancer, a disease driven
in part by abnormal testosterone activity, which affects one in six
American men.
Debiopharm of Switzerland has won approval for a three-month depot
formulation of Pamorelin (triptorelin pamoate), a drug to treat
prostate cancer, based on its proprietary polymer-based drug
delivery technology.
A new activity-based proteomics screening technique has allowed
scientists to identify active targets and simultaneously screen for
their inhibitors. The screening technique has already revealed that
orlistat, an anti-obesity drug,...
Drug delivery company Atrix Laboratories confirmed this week that
the German regulatory authority, Bundesinstitut fur Arzneimittel
und Medizinprodukte (BfArM), had recently completed a successful
inspection of Atrix's manufacturing...
